After joining the upper echelons of the biopharma industry’s top-paid CEOs in 2018, Seagen helmsman Clay Siegall, Ph.D., could reclaim a spot for 2021.
Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC .
Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer Paris, March 16, 2022. Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusiv.
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to